Clinical Trial

Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated April 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-12-07; most recent amendment 2026-04-28.
Status change: Active, Not Recruiting → Completed 2026-04-28
Status change: Recruiting → Active, Not Recruiting 2024-09-10
Status change: Not Yet Recruiting → Recruiting 2023-06-02
Trial Details
NCT Number NCT05653492
Lead Sponsor University of Rochester
Collaborators: Renal Research Institute
Conditions Pediatric Kidney Disease
Enrollment 12 participants
Start Date 2023-05-15
Primary Completion 2025-04-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-19